Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox for trigeminal neuralgia (RCT with biomarker analysis)
2023-504567-17-00Phase 3Authorised
- Sponsor
- Rigshospitalet
- Start
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in trigeminal neuralgia (TN) and Idiopathic Trigeminal Neuralgia (TN) comparing Botox with Placebo (2 arms). Planned start Aug 2023; status: authorised.
02
Drugs
botulinum toxin type A
03
Conditions
trigeminal neuralgia (TN)Idiopathic Trigeminal Neuralgia (TN)
Beyond the preview
Go deeper on 2023-504567-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504567-17-00.